ArticleJournal of pharmacy & bioallied sciences2024
Association of Triglycerides and HbA1c Levels with Stages of Invasive Ductal Breast Cancer: A Prospective Study.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This prospective study investigates the association between triglyceride (TG) levels and HbA1c values with different stages of invasive ductal breast cancer (IDC) in female patients. Metabolic alterations, including dyslipidemia and hyperglycemia, are increasingly recognized as potential factors associated with cancer progression. Methods: A total of 150 female patients diagnosed with IDC were included in the study, categorized into four stages of the disease. Triglyceride levels were measured using colorimetry, and HbA1c values were determined using the ion exchange resin method. Descriptive statistics and distributions of TG and HbA1c values were analyzed across the cancer stages. Results: In Stage 1, patients had a mean TG level of 347.5 mg/dL and a mean HbA1c of 10.2%. These values declined in subsequent stages, with Stage 4 patients showing a mean TG level of 208.6 mg/dL and a mean HbA1c of 6.9%. A majority of Stage 1 patients (n = 35) had TG levels between 200 and 499 mg/dL, while Stage 4 had the highest number of patients with TG levels below 150 mg/dL (n = 6). Additionally, a significant proportion of Stage 1 patients had HbA1c values ≥10% (n = 17), indicating poor glycemic control. As the disease progressed, this proportion decreased, with only two patients in Stage 4 having HbA1c levels ≥10%. Conclusion: This study suggests a correlation between lower TG and HbA1c levels and more advanced stages of IDC. These findings highlight the importance of metabolic factors in IDC progression and may inform future research on potential therapeutic targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.